Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.

Purpose: We assessed the efficacy and toxicity of a fixed dose of docetaxel and prednisone, combined with escalating doses of gemcitabine (DGP). The primary endpoint was PSA response.

Methods: Fifteen patients were enrolled in the phase I and 50 patients entered the phase II.